Plasma levels of AGE peptides in type 1 diabetic patients are associated with serum creatinine and not with albumin excretion rate: Possible role of AGE peptide-associated endothelial dysfunction

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 662-670

  Schalkwijk, Casper G ^a,b   Ter Wee, Piet M ^a   Stehouwer, Coen D A ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced glycation end product; Age peptides; Diabetes; Renal failure

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEMOGLOBIN A1C; PEPTIDE DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

AGE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE MARKER; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXCRETION; FLUORESCENCE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MICROALBUMINURIA; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 23744514145     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.075     Document Type: Conference Paper

References (19)

1. CULLETON, B.F., M.G. LARSON, P.W. WILSON, et al. 1999. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 56: 2214-2222.
2. COLLINS, A.J., S. LI, J.Z. MA & C. HERZOG. 2001. Cardiovascular disease in end-stage renal disease patients. Am. J. Kidney Dis. 38: S26-S29.
3. MIYATA, T., S. SUGIYAMA, A. SAITO & K. KUROKAWA. 2001. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int. Suppl. 78: S25-S31.
4. FORBES, J.M., M.E. COOPER, M.D. OLDFIELD & M.C. THOMAS. 2003. Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. 14: S254-S258.
5. THORPE, S.R. & J.W. BAYNES. 2003. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25: 275-281.
6. DEUTHER-CONRAD, W., S. FRANKE, M. SOMMER & G. STEIN. 2001. Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteins. Kidney Int. Suppl. 78: S63-S66.
7. MAKITA, Z., S. RADOFF, E.J. RAYFIELD, et al. 1991. Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 325: 836-842.
8. SHARP, P.S., S. RAINBOW & S. MUKHERJEE. 2003. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet. Med. 20: 575-579.
9. THOMAS, M.C., C. TSALAMANDRIS, R. MACISAAC, et al. 2004. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int. 66: 1167-1172.
10. WROBEL, K., K. WROBEL, M.E. GARAY-SEVILLA, et al. 1997. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin. Chem. 43: 1563-1569.
11. MIYATA, T., C. VAN YPERSELE DE STRIHOU, K. KUROKAWA & J.W. BAYNES. 1999. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int. 55: 389-399.
12. VLASSARA, H. 1996. Advanced glycation end-products and atherosclerosis. Ann. Med. 28: 419-426.
13. ROSS, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
14. SCHALKWIJK, C.G., D.C. POLAND, W. VAN DIKJ, et al. 1999. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42: 351-357.
15. MANN, J.F., H.C. GERSTEIN, J. POGUE, et al. 2001. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134: 629-636.
16. MUNTNER, P., J. HE, L. HAMM, et al. 2002. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J. Am. Soc. Nephrol. 13: 745-753.
17. BUCALA, R., Z. MAKITA, G. VEGA, et al. 1994. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA 91: 9441-9445.
18. BASTA, G., A.M. SCHMIDT & R. DE CATERINA. 2004. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 63: 582-592.
19. TOHDA, G., K. OIDA, Y. OKADA, et al. 1998. Expression of thrombomodulin in atherosclerotic lesions and mitogenic activity of recombinant thrombomodulin in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 18: 1861-1869.